Former FrontPoint fund manager Joseph Skowron pleaded guilty to an insider trading charge related to Human Genome Sciences' hepatitis C drug. Skowron received tips on clinical trials outcomes from hepatitis C expert and former HGS advisor Yves Benhamou that helped his fund avoid more than $30 million in losses, according to Bloomberg. Report